Ciclesonide in wheezy preschool children with a positive asthma predictive index or atopy

Summary Background Few large-scale studies have examined inhaled corticosteroid treatment in preschool children with recurrent wheeze. We assessed the effects of ciclesonide in preschool children with recurrent wheeze. Methods We included children 2–6 yrs with recurrent wheeze and a positive asthma...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine 2011-11, Vol.105 (11), p.1588-1595
Main Authors: Brand, Paul L.P, Luz García-García, María, Morison, Adrian, Vermeulen, Jan H, Weber, Heinrich C
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Asthma
Asthma - drug therapy
Asthma - physiopathology
Asthma predictive index
Atopy
Biological and medical sciences
Bronchodilator Agents - therapeutic use
Child
Child, Preschool
Children & youth
Chronic obstructive pulmonary disease, asthma
Ciclesonide
Clinical trials
Disease Progression
Dose-Response Relationship, Drug
Double-Blind Method
Drug therapy
Female
Forced Expiratory Volume - drug effects
Humans
Male
Medical sciences
Pneumology
Predictive Value of Tests
Pregnenediones - therapeutic use
Preschool children
Pulmonary/Respiratory
Respiratory Sounds - drug effects
Respiratory Sounds - physiopathology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Few large-scale studies have examined inhaled corticosteroid treatment in preschool children with recurrent wheeze. We assessed the effects of ciclesonide in preschool children with recurrent wheeze. Methods We included children 2–6 yrs with recurrent wheeze and a positive asthma predictive index or aeroallergen sensitization to, excluding patients with episodic viral wheezing. After a 2–4-week baseline period, patients with ongoing symptoms or rescue medication use were randomised to once-daily ciclesonide 40, 80, 160 μg or placebo for 24 weeks. Results The number of wheeze exacerbations requiring systemic corticosteroids was unexpectedly low in all groups: 25 (10.2%) in placebo group, as compared to 11 (4.4%), 18 (7.3%), and 17 (6.7%) in ciclesonide 40, 80, and 160 μg, respectively. The difference in time to first exacerbation was not significantly different between groups ( p  = 0.786), but the difference in exacerbation rates between placebo and the pooled ciclesonide groups was ( p  = 0.03). Large and significant ( p  
ISSN:0954-6111
1532-3064
DOI:10.1016/j.rmed.2011.07.017